euro-biopharma-ethnopharmacology-2017-tracks

13 / 28

Notes:
Volume 6, Issue 4 (Suppl) Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 29
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6th International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4th EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Steroid-harboring nanoparticles provide anti-inflammatory response with less adverse effects
K Kvell, B Kollar, B Horvath, A Szechenyi and Sz Pal
University of Pécs, Hungary
Statement of the Problem: Steroids are acknowledged anti-inflammatory drugs used in multiple conditions, including autoimmune
disease. Steroids provide strong suppression of inflammation however, their long-term utilization triggers numerous adverse
effects including obesity, diabetes, osteoporosis, edema retention etc. As a result, only inflammatory flares are treated with steroid
compounds, for short term.
Methodology & Theoretical Orientation: Our collaborative research team has produced nanoparticles of specific size harboring
steroid compounds. In theory, due to their specific size, steroid-harboring nanoparticles trigger phagocytosis in monocytes and
macrophages, but leave other (non-phagocytic) cells unaltered.
Findings: Our human in vitro data indicate that steroid particles show potent anti-inflammatory effect on monocytes / macrophages,
equivalent to that of steroid solution. However, their adverse effects are reduced using non-phagocytic cells. Liver cells, for example,
show increased viability with steroid particles as opposed to steroid solution.
Conclusion & Significance: Our working hypothesis was that steroid-particles of a specific size range can preferentially target
monocytes/macrophages, the major mediators of inflammation. Other (non-phagocytic) cell types shall largely be unaltered by
steroid particles, as opposed to steroid solution. This is confirmed by our data. Our technology allows for the production of regular
steroid compounds with significantly reduced side effects, with the promise of long-term use in human.
Biography
K Kvell, MD PhD has primary expertise in Immunology and Biotechnology. He works in the field of Immune Senescence and its relation to steroid compounds.
Currently he is working at the Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, at the University of Pecs, Hungary. He is currently involved in
interdisciplinary research utilizing steroid compounds and nanoparticles. This field encouraged the collaborative research team to develop novel drug delivery
strategies of steroid treatment, to allow for targeted steroid treatment with potent anti-inflammatory effect, yet with reduced level side effects.
K Kvell et al., Clin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-025